CENTER FOR FOOD SAFETY

June 27, 2022

Office of Pesticide Programs
Environmental Protection Agency
1200 Pennsylvania Ave., NW
Washington, DC 20460–0001

RE: Docket EPA-HQ-OPP-2015-0459
Comments on proposed interim registration decision for propiconazole

Center for Food Safety appreciates the opportunity to comment on EPA's proposed interim registration decision for the fungicide propiconazole, on behalf of itself and its 970,000 members and supporters. Center for Food Safety (CFS) is a public interest, nonprofit membership organization with offices in Washington, D.C., San Francisco, California, and Portland, Oregon. CFS's mission is to empower people, support farmers, and protect the earth from the harmful impacts of industrial agriculture. Through groundbreaking legal, scientific, and grassroots action, CFS protects and promotes the public's right to safe food and the environment. CFS has consistently supported comprehensive EPA review of registered pesticides and individual inert ingredients.

Introduction

Propiconazole is a broad-spectrum, systemic fungicide that stops the growth of fungi by blocking the synthesis of sterols, key components of fungal cell walls. It belongs to the triazole class of demethylase inhibitor (DMI) fungicides, and in particular inhibits the CYP51 enzyme.

Propiconazole is registered for use on many fruits, vegetables, tree nuts, cereal grains including corn, wheat and rice, soybeans and sugar beets, as well as turfgrass and ornamentals. Total agricultural and non-agricultural use on plants has risen from roughly 0.5 million lbs./year in the 1990s and early 2000s to 3 million lbs./year today (excluding seed treatments), with over 80% applied to wheat, corn and soybeans (see graph below). It is applied as a seed treatment, foliar spray, dip treatment, and via tree injection and chemigation. Propiconazole is also used extensively as an antimicrobial, with over 20 million lbs. used annually as a wood preservative: primarily for playground structures, decks, picnic tables, patios, walkways and other residential applications. An unreported amount of propiconazole is used for a wide range of other preservative applications: carpets, paints, metalworking fluids, paper and paperboard products, among others.

Several features of propiconazole and its use deserve particular consideration. First, because it is one of many DMI/triazole fungicides with the same mode of action in fungi, and similar effects on human health and non-target organisms, its putative benefits and impacts must be viewed in the broader context of its class. Second, propiconazole (as of 2016) was the most heavily used triazole fungicide, and triazole use overall is dramatically increasing. There are at least 15 DMI/triazole fungicides applied in the U.S., and their collective use as of 2016

(excluding seed treatments) was nearly 7-fold greater than in 1992, and over 5-fold (434%) greater since just 2006 (Toda et al. 2021). Finally, propiconazole and other members of its class are quite persistent in the environment.





Source: US Geological Survey, https://water.usgs.gov/nawqa/pnsp/usage/maps/show_map.php?year=2019&map=PROPICONAZOLE&hilo=L&disp=Propiconazole.

Relevant Legal Standards

Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA)

Under FIFRA, EPA licenses the sale, distribution, and use of pesticides, including herbicides, through the process of registration.[1] EPA can register a pesticide only upon determining that "it will perform its intended function without unreasonable adverse effect on the environment,"[2] and that "when used in accordance with widespread and commonly recognized practice it will not generally cause unreasonable adverse effects on the environment."[3] FIFRA defines "unreasonable adverse effects on the environment" as "any unreasonable risk to man or the environment, taking into account the economic, social, and environmental costs and benefits of the use of any pesticide."[4]

FIFRA's registration review process is mandated at 7 U.S.C. § 136a(g). FIFRA requires that pesticide registrations are periodically reviewed, and that EPA "shall by regulation establish a procedure for accomplishing the periodic review of registrations."[5] EPA adopted regulations pursuant to this provision in 2006, which state that each pesticide is required to be reviewed every 15 years.[6] Registration review is intended to ensure that each active ingredient's registration is based on current science, including its effects on human health and the environment. If a product "fails to satisfy the FIFRA standard for registration, the product's registration may be subject to cancellation or other remedies under FIFRA."[7]

Endangered Species Act

As recognized by the Supreme Court, the Endangered Species Act (ESA) is "the most comprehensive legislation for the preservation of endangered species ever enacted by any nation."[8] The ESA's statutory scheme "reveals a conscious decision by Congress to give endangered species priority over the 'primary missions' of federal agencies."[9] Federal agencies are obliged "to afford first priority to the declared national policy of saving endangered species."[10]

Section 7(a)(2) of the ESA requires every federal agency to consult the appropriate federal fish and wildlife agency—the U.S. Fish and Wildlife Service (FWS), in the case of land and freshwater species and the National Marine Fisheries Service (NMFS) in the case of marine species—to "insure" that the agency's actions are not likely "to jeopardize the continued existence" of any listed species or "result in the destruction or adverse modification" of critical habitat.[11] The ESA's implementing regulations broadly define agency action to include "all activities or programs of any kind authorized, funded or carried out … by federal agencies," including the granting of permits and "actions directly or indirectly causing modifications to the

[1] 7 U.S.C. § 136a(5)(D).
[2] *Id*. § 136a(c)(5)(C).
[3] *Id*. § 136a(c)(5)(D).
[4] *Id*. § 136(bb).
[5] *Id*. § 136a(g)(1)(A).
[6] 40 C.F.R. §§ 155.40-155.58.
[7] *Id*. § 155.40(a).
[8] *Tenn. Valley Authority v. Hill*, 437 U.S. 153, 180 (1978).
[9] *Id*. at 185.
[10] *Id.*
[11] 16 U.S.C. § 1536(a)(2); *see also* 50 C.F.R. § 402.01(b).

land, water or air."[12] In June 2022, the Ninth Circuit confirmed that interim registration review decisions are affirmative agency actions for which consultation is required. *Nat. Res. Def. Council v. EPA*, 2022 WL 2184936, at *18 (9th Cir. June 17, 2022). A species' "critical habitat" includes those areas identified as "essential to the conservation of the species" and "which may require special management considerations or protection."[13]

EPA is required to review its actions "at the earliest possible time" to determine whether the action may affect listed species or critical habitat.[14] To facilitate compliance with Section 7(a)(2)'s prohibitions on jeopardy and adverse modification, the ESA requires each federal agency that plans to undertake an action to request information from the expert agency "whether any species which is listed or proposed to be listed [as an endangered species or a threatened species] may be present in the area of such proposed action."[15] If FWS/NMFS advises the agency that listed species or species proposed to be listed may be present, the agency must then prepare a biological assessment for the purpose of identifying any such species that are likely to be affected by the proposed agency action.[16]

If, based on a biological assessment, an agency determines that its proposed action may affect any listed species and/or their critical habitat, the agency generally must engage in formal consultation with FWS/NMFS.[17] At the end of the formal consultation, FWS/NMFS must provide the agency with a "biological opinion" detailing how the proposed action will affect the threatened and endangered species and/or critical habitats.[18] If FWS/NMFS concludes that the proposed action will jeopardize the continued existence of a listed species or result in the destruction or adverse modification of critical habitat, the biological opinion must outline "reasonable and prudent alternatives" to the proposed action that would avoid violating ESA section 7(a)(2).[19]

Pending the completion of formal consultation with the expert agency, an agency is prohibited from making any "irreversible or irretrievable commitment of resources with respect to the agency action which has the effect of foreclosing the formulation or implementation of any reasonable and prudent alternative measures."[20]

Human Health Concerns and Assessment Deficiencies

Liver toxicity

The liver is propiconazole's primary target organ in mouse and rat studies. Effects in mice include increased liver weights and enlarged livers, together with an increase in liver enzymes, a decrease in cholesterol, and increased incidence and severity of hepatocellular hypertrophy as well as necrosis of liver cells. These effects progressed to benign and malignant

[12] 50 C.F.R. § 402.02 (emphasis added).
[13] 16 U.S.C. § 1532(5)(A).
[14] 50 C.F.R. § 402.14(a).
[15] 16 U.S.C. § 1536(c)(1); *see also* 50 C.F.R. § 402.12(c).
[16] *Id.*
[17] 50 C.F.R. § 402.14.
[18] 16 U.S.C. § 1536(b); 50 C.F.R. § 402.14.
[19] 16 U.S.C. § 1536(b)(3)(A).
[20] 16 U.S.C. § 1536(d).

tumors in male mice over the course of a two-year carcinogenicity study (EPA 3/21/22, p. 27). Mice also experienced fatty changes (vacuolation) to the liver (Ibid., p. 110).

Rats fed propiconazole also experienced adverse liver effects, for instance liver lesions in a two-year chronic/carcinogenicity study that occurred at lower doses than those in the rat subchronic study. There was an increased incidence of vacuolation (i.e. fatty changes) and/or hepatocellular hypertrophy in both parental rats and offspring in a two-generation reproduction study (Ibid.).

EPA officially regards propiconazole as a Group C "possible human carcinogen" based on mouse studies (Ibid., pp. 31-32). Interestingly, however, elsewhere EPA scientists assume with far less uncertainty than the "possible" modifier suggests that propiconazole is a mammalian carcinogen that causes hepatocellular adenomas and carcinomas (Skolness et al. 2013). In fact, EPA made propiconazole a case study of carcinogenesis for a paper investigating the use of new computational and molecular tools for elucidating the mode of action of carcinogens in risk assessments (EPA 2011). Propiconazole deserves a hazard descriptor of "likely to be carcinogenic to humans."

Need for Cumulative Exposure and Risk Assessment of Triazole Fungicides

Triazole fungicides clearly meet EPA's criteria for designation as a common mechanism group (CMG), for which a cumulative risk assessment must be carried out, as mandated by the Food Quality Protection Act (EPA 1/29/99, 1/14/02). They have similar chemical structures, the liver is their primary target organ, they exert similar toxic effects on the liver, and do so via common mechanisms of toxicity. In more modern language, they share a mode of action and adverse outcome pathways for several endpoints (MOA/AOP) (EPA 4/12/16). The European Food Safety Authority conducted a cumulative assessment of triazoles over a decade ago, forming cumulative assessment groups for developmental effects observed following acute exposure (cranio-facial malformations), and for liver toxicity as the chronic endpoint (EFSA 2009).

A review of registrant studies submitted to European regulators found that propiconazole and all or most of 10 other triazole fungicides that were reviewed induced hepatocellular hypertrophy, hepatic cell degeneration or death, fatty changes, inflammation and foci of cellular alteration in the liver, and hepatocellular tumors, among other adverse liver effects (Nielsen et al. 2012). As discussed further below, they exert these effects by activating nuclear receptors that induce the production of cytochrome P_{450} detoxification enzymes in the liver, causing an increase in cellular organelles (endoplasmic reticulum, peroxisomes and mitochondria) that is responsible for hepatic cell enlargement (hypertrophy). Hypertrophy is sometimes regarded as an adaptive effect, but persistent hypertrophy is adverse, particularly when it progresses to other adverse liver impacts as it does with triazoles (Nielsen et al. 2012). There are at least two endpoints, shared by most triazoles, that should be the focus of a cumulative assessment: fatty changes and carcinogenicity.

Fatty changes

The liver is the body's primary detoxification organ, and many industrial chemicals and pesticides are hepatotoxic. The most common hepatic pathology induced by chemicals is fatty liver (Al-Eryani et al. 2015) – the accumulation of lipids in liver cells – which can progress to

more serious conditions, steatohepatitis and cirrhosis, which in turn are the most important risk factors for liver cancer (Wahlang et al. 2013). According to EPA scientists, fatty liver disease is "a growing epidemic" that affects 20-30% of the U.S. population (Angrish et al. 2016), while the incidence of liver cancer it predisposes to tripled from 1975 to 2005 (Altekruse et al. 2009).

In a review of chemical exposure and rodent toxicology databases maintained by the EPA and the National Toxicology Program, Al-Eryani et al. (2015) found that 54 pesticides, including 22 fungicides, many of them triazoles, caused fatty changes in the liver. In a similar review of registrant submissions to the European Union, 10 triazole fungicides induced fatty changes in the liver (Nielsen et al 2012). Altogether, at least 15 triazole fungicides induce lipid accumulation in liver cells (Table 1).

Table 1: Triazole Fungicides That Induce Fatty Changes in the Liver

Fungicide	Regulatory Authority (US, EU)	Comments
Bromuconazole	US	
Cyproconazole	US	
Difenoconazole	US, EU	
Epoxiconazole	EU	
Flusilazole	US, EU	
Hexaconazole	US	
Metconazole	EU	
Paclobutrazole	US	
Propiconazole	US, EU	
Prothioconazole	EU	
Tebuconazole	EU	
Tetraconazole	US, EU	For US, see EPA (12/11/20), e.g. p. 16: "fat deposition," "marked centrilobular fat"
Triadimefon	US	
Triadimenol	US, EU	Primary metabolite of triadimefon
Triticonazole	EU	

Sources: Al-Eryani et al. (2005) for US; Nielsen et al. (2012) for EU. US = United States, EU = European Union. Listings in one rather than both jurisdictions does not necessarily mean differing assessments of this endpoint. Rather, it may be that particular triazoles are registered in only the US or the EU, or were at the time of the source publications.

Propiconazole, along with difenoconazole and tebuconazole, was shown to promote accumulation of triglycerides in human HepaRG cell culture, with all three activating the pregnane-X-receptor (PXR) (Lasch et al. 2021). The critical role of PXR was demonstrated by a second study of propiconazole and tebuconazole (Knebel et al. 2019). Both triazoles induced expression of steatosis-related genes and triglyceride accumulation in HepaRG cells via interactions with several nuclear receptors – the constitutive androstane receptor (CAR), peroxisome proliferator-activated receptor alpha (PPARα), and PXR. But in experiments with HepaRG subclones with knockouts of either PXR or CAR, triazole-induced triglyceride accumulation was abolished only with the PXR, not the CAR, knockout, demonstrating the critical role of PXR in mediating lipid accumulation triggered by triazoles.

Other studies provide still more supporting evidence. In a 28-day rat feeding trial with cyproconazole, epoxiconazole and prochloraz (an azole but not triazole fungicide), Heise et al. (2005) found hepatocellular hypertrophy and occasional necrosis of liver cells for all three compounds, increased absolute and relative liver weights for the two triazoles, and hepatic cell vacuolization with cyproconazole. A gene expression analysis found that triazoles induced expression of more than 30% of the genes in four toxicity pathways, including two involved in lipid metabolism: steatosis and phospholipidosis. Linkages between gene expression and histopathology were also found: vacuolization of hepatic cells is associated with steatosis; while cyproconazole also upregulated fatty acid synthase and transporter genes. Heise et al. (2007) tested combination of the same three fungicides in rats, and found similar effects as for the individual compounds, with dose additivity sufficient to account for combined effects. In 28-day rat feeding trials, Kwon et al. (2021) found that still another triazole, flutriafol, induced fatty infiltration of the liver by impairing liver metabolism and inducing apoptosis.

In a review article on the hepatic impacts of triazole fungicides, Marx-Stoelting et al. (2020) lay out adverse outcome pathways for liver hypertrophy and liver steatosis that link the molecular, cellular and tissue/organ level changes wrought by triazole exposure (see below). For hypertrophy, the molecular initiating events are triazole activation of the aryl hydrocarbon (AHR), CAR and PXR nuclear receptors, followed by four key events that mediate the adverse outcome on the tissue/organ level: hypertrophy of the liver:

1) Increased expression of CYP genes, with AHR, CAR and PXR preferentially but not exclusively inducing CYP families CPY1A1 and 1A2, CYP2B and CYP3A, respectively;
2) Increased expression of the corresponding CYP enzymes;
3) Proliferation of endoplasmic reticulum and other organelles to produce the additional CYP enzymes; and
4) Increased size of hepatic cells ensuing from the additional organelles.



Figure 2. Schematic delineation of a nuclear receptor-dependent molecular pathway leading to hepatocellular hypertrophy. Nuclear receptor activation functions as molecular initiating event. Abbreviation: ER, endoplasmic reticulum.

Figure 2. Adverse Outcome Pathway for Liver Hypertrophy. Source: Marx-Stoelting et al. (2020).



Figure 3. Schematic delineation of the AOP for hepatocellular steatosis. The figure was adapted from [58]. Abbreviations: FXR, farnesoid-X-receptor, GR, glucocorticoid receptor.

Figure 3. Adverse Outcome Pathway for Liver Steatosis. Source: Marx-Stoelting et al. (2020).

Hypertrophy of hepatic cells and the liver is a sensitive indicator of liver damage, for instance lipid accumulation. The adverse outcome pathway for hepatic steatosis is more complicated than that for hypertrophy, in that it involves multiple molecular initiating events, each activating a different toxic pathway with different key events, the cumulative outcome of which is steatosis (see Fig. 3).

Not every triazole fungicide will initiate each of these pathways in the same way on the molecular level, nor is it reasonable to demand that they do, in order to find that triazoles constitute a common mechanism group. Each pathway contributes to the same outcome, steatosis, whether through inhibition of fatty acid degradation via activation of PPRAα, increased fatty acid synthesis through upregulation of fatty acid synthase genes, and/or via increased influx of fatty acids into hepatic cells via increased expression of the corresponding transport gene.

The fact that at least 15 triazoles trigger fatty changes in the liver (Table 1), coupled with abundant evidence that they activate nuclear receptors (particularly PRX) in ways that lead to this outcome, is more than enough scientific justification to require EPA to conduct a cumulative exposure and risk assessment of triazole fungicides for this endpoint.

Carcinogenicity

A second endpoint for which EPA must cumulatively assess triazoles is carcinogenicity. EPA itself recognized the need for this in 2000, when another triazole fungicide, tetraconazole, was first registered. The Agency's Carcinogenicity Peer Review Committee noted that tetraconazole was one of the seven triazole fungicides (out of 10) that induced liver tumors in mice, and propiconazole was one of the seven (EPA 1/11/00). EPA had recognized and properly assigned weight to this striking common effect of triazole herbicides as long ago as 1994, in an assessment of difenoconazole: "Difenoconazole is a member of a class of chemicals, many of

which have been associated with liver tumors in CD-1 mice" (EPA 7/27/94, p. 3). EPA then noted that eight structurally related triazole compounds have also been found to induce hepatocellular tumors (EPA 7/27/94, pp. 14-15). Six years later EPA made a similar argument to support its likely to be carcinogenic designation of tetraconazole (EPA 1/11/00). A review of EU regulatory submissions identified seven triazoles that induced neoplasms (Nielsen et al 2012), for a total of 13 (Table 2).

Table 2: Triazole Fungicides That Induce Tumors

Fungicide	Regulatory Authority (US, EU)	Comments
Cyproconazole	US	
Difenoconazole	US, EU	
Epoxiconazole	EU	
Etaconazole	US	
Fenbuconazole	US	
Flusilazole	EU	
Metconazole	EU	
Propiconazole	US, EU	
Tebuconazole	US, EU	
Tetraconazole	US, EU	
Triadimefon	US	Also referred as Bayleton
Triadimenol	US	Primary metabolite of triadimefon, aka Baytan
Uniconazole	US	

Sources: EPA (7/27/94) for US; Nielsen et al. (2012) for EU. US = United States, EU = European Union. Listings in one rather than both jurisdictions does not necessarily mean differing assessments of this endpoint. Rather, it may be that particular triazoles are registered in only the US or the EU, or were at the time of the source publications.

Pesticide industry scientists tend to discount the carcinogenic effects of non-genotoxic, nuclear receptor-activating compounds (such as triazoles) in rodents as not relevant to humans (Elcombe et al. 2014). They do this by defining the mode of action of such compounds as equivalent to that of phenobarbital (PB), a model CAR activator that induces tumors in mice, but which epidemiology suggests may not induce tumors in humans. However, EPA Office of Research and Development scientists dispute this simplistic branding of rodent carcinogens that elicit some of the same hepatic toxicological responses as phenobarbital as then automatically irrelevant to humans (Nesnow et al. 2009). They showed that propiconazole and triadimefon, for instance, have gene expression profiles that differ substantially from phenobarbital's, their mechanisms of tumorigenic action are likely to differ, and hence the triazoles' induction of liver tumors in mice might well be relevant to humans.

Finally, the fact that so many triazoles induce hypertrophy, as well as steatosis, which is a risk factor for liver cancer, argues for the necessity of conducting a cumulative assessment of triazoles for liver cancer as well.

Cumulative Risk Assessment of 1,2,4-Triazole and its Conjugates

Triazole fungicides share an eponymous structural feature, 1,2,4-triazole, a five-membered aromatic ring comprising 3 nitrogen and 2 carbon atoms. 1,2,4-triazole and its conjugates (triazole-alanine and triazole acetic acid, TA and TAA, respectively) are common metabolites of these fungicides (EPA 2/7/06). Due to concerns over the toxicity of these

metabolites, in the year 2000 EPA delayed granting any new triazole registrations pending more toxicology and exposure data for the metabolites (Ibid.).

To fill the data gaps, EPA issued a data call-in for studies on the developmental neurotoxicity, acute neurotoxicity, and carcinogenicity of free 1,2,4-triazole, and for a developmental toxicity study (rabbits) for both TA and TAA; a chronic rat study with neurological evaluations for TA; and a combined 90-day feeding/neurotoxicity study (rat) for TAA (Ibid., p. 6). The registrant group US Triazole Task Force (USTTF) did not respond to the 2002 call-in, and requested waivers from EPA in 2003 that EPA denied. The studies were still outstanding in 2005, when USTTF submitted renewed waiver requests (Ibid.).

Registrants to this day have not submitted the studies EPA demanded 15 years ago as a condition for any further registrations of triazoles (Ibid., p. 6, see also EPA 3/10/22, p. 8).

Developmental Neurotoxicity (DNT) Study

The developmental neurotoxicity (DNT) study is designed to capture adverse neurological impacts of a pesticide when a fetus's or infant's developing nervous system is exposed, an exposure window when incredibly low doses can have profoundly destabilizing effects on nervous system architecture. Lifelong adverse impacts such as reduced IQ, developmental delays and attention-deficit hyperactivity disorder have been linked to fetal/infant exposure to extremely low levels of chlorpyrifos, for instance. The DNT study was called for due to substantial evidence of 1,2,4-triazole's neurotoxicity in other animal trials, including:

- Neuropathological lesions in the brain and peripheral nervous system;
- Decreases in brain weight, including in offspring at doses that did not cause the same effect in adults in the rat reproduction study;
- Tremors, muscle fasciculations, decreased arousal, decreased rearing, decreased motor activity in rats, and excessive salivation, hyperpnea, lacrimation and head tilt in rabbits (EPA 2/7/06, pp. 17, 20).

Registrants apparently decided to ignore EPA's demands, because the DNT study has still not been submitted (EPA 5/16/18, p. 22600). Neither did EPA cease registration of new uses and new triazoles until it had received this study, as it had demanded in 2006 (EPA 2/7/06, p. 6).

Chronic toxicity/carcinogenicity study

EPA had also required a chronic toxicity/oncogenicity study on 1,2,4-triazole in male rats and female mice to determine whether this metabolite was the common cause of liver tumors found with so many triazoles (Ibid., p. 6). We find no record this study has been submitted either.

Developmental toxicity study in rabbits

EPA demanded this study to fulfill "a particularly important data gap" for both TA and TAA because there were no rabbit tests with either of these compounds, the rabbit was the most sensitive species to 1,2,4-triazole, and because of the gravity of the adverse impact (mortality)

ensuing from just a single dose of 1,2,4-triazole (45 mg/kg) in rabbits (Ibid., p. 47). We see no evidence these studies on TA or TAA have been submitted.

EPA applied arbitrary safety factors in an attempt to compensate for the missing studies, but has no way of knowing whether they are adequate. In any case, these safety factors are intended only as a temporary stopgap until the relevant studies are submitted, permitting a data-based assessment. Here, the relevant studies have been outstanding for at least 15 years, a period during which EPA has issued numerous registrations for new uses of triazoles.

Agricultural Triazole Use Breeds Resistance to Triazole Antifungal Drugs in Human Pathogens

Fungal diseases are spiraling worldwide, with the global mortality rate from fungal infections now exceeding that from malaria or breast cancer, and rivalling deaths from tuberculosis and HIV (Fisher et al. 2018). There are nine times more antifungal compounds for crop disease than for animal infections, and just four classes of antifungals licensed for human use (Ibid.). Triazoles are the dominant compounds used to treat crops, animals and humans; are the only class used in both medicine and agriculture (Ibid.).

Drivers of resistance in plant and human pathogens share some similarities. In modern industrial agriculture, breeding has long been primarily concerned with increasing yield, and conducted with use of pesticides to eliminate pest and disease pressure. These factors lead to loss of disease resistance, and increasing dependence on fungicides accompanied by accelerating resistance. Ever more people are at risk of fungal infection due to age, medical interventions or HIV infections. Immune suppression with chemotherapy or organ transplantation increases susceptibility to opportunistic fungi, leading to greater use of antifungal drugs and pathogens resistant to them. Global movement of people and goods promotes rapid spread of fungal pathogens of crops and people (Ibid.).

Candida auris was first described in 2009 in Japan, and has spread worldwide primarily as a nosocomial pathogen resistant to all clinical antifungal medications (Ibid., Richtel and Jacobs 2019), one of several fungal pathogens on the rise (Fisher et al 2018).

Invasive aspergillosis is a serious and frequently fatal lung disease that mainly affects people who are immunocompromised: for instance, those recovering from tuberculosis, with pulmonary disease, or in conjunction with organ transplantation (for this discussion generally, see Toda et al. 2021 unless otherwise cited). It also afflicts millions of asthmatics worldwide, greatly exacerbating their disease, with conditions known as allergic bronchopulmonary aspergillosis and severe asthma with sensitization (Bowyer and Denning 2014).

The major pathogen of this disease is *Aspergillus fumigatus*, which is commonly found in the environment (e.g. decaying plant matter), has unusually high tolerance to heat and so propagates quite well in the human body, and is not known to cause plant disease. The major medications (and only ones available in oral form) used to treat this disease are triazole antifungal medicines such as itraconazole, voriconazole and posoconazole.

Over the past several decades, there has been an extremely concerning rise in invasive aspergillosis caused by *A. fumigatus* that is resistant to triazole antifungals; in such virtually untreatable infections, the mortality rate rises to 42-88%.

Resistant *A. fumigatus* has been reported in patients with aspergilloma undergoing long-term therapy with triazoles antifungals. In this disease, a fungal mass grows in a lung cavity, where it can reproduce. These resistant strains induced by medical antifungal use are characterized by a great diversity of resistance mechanisms (Snelders et al. 2012). However, there is a large and growing body of scientific literature demonstrating that agricultural use of triazole fungicides is another source of this growing resistance problem.

First, resistant strains of *A. fumigatus* have been isolated from triazole-naïve patients around the world, infections that cannot be due to treatment of these individuals with the antifungals. In addition, a disproportionate number of resistant strains isolated from patients in the Netherlands, an early site for emergence of this problem, have a particular resistance mechanism – a tandem repeat of 34 base pairs in the *cyp51* promoter region and a leucine to histidine substitution at codon 98 in the coding region (TR_{34}/L98H) – that is also commonly found in the environment. This TR34/L98H strain was first cultured from a patient in the Netherlands in 1998, following close on the heels of a ramping up of agricultural triazole use there and in Europe generally from 1990-1996 (Snelders et al. 2012).

Moreover, the first medical antifungal (itraconazole) was only licensed in 1997 (Zhang J et al. 2017), very little time for it to have driven selection of the resistant strain noted above, even assuming the first TR34/L98H strain ***discovered*** in a patient were the first such to ***emerge,*** which appears unlikely. Additional reasons to doubt that medical use is responsible for all or even most resistance are, first, the miniscule amounts used to treat human disease relative to agricultural use; and the fact that itraconazole is excreted from the body in non-active form, making selection for resistance in sewage or receiving waters unlikely (Bowyer and Denning 2014).

The agricultural triazoles that most resemble their medical counterparts – both structurally and in terms of their docking at the CYP51 binding site – are difenoconazole, bromuconazole, epoxiconazole, propiconazole and tebuconazole. In susceptibility testing, these five triazoles (as well as metconazole and imazalil) showed the greatest dissimilarity in activity on wild-type versus resistant L98H isolates, as measured by minimum inhibitory concentration (Snelders et al. 2012). Moreover, these same five triazoles selected for *A. fumigatus* strains with cross-resistance to the medical antifungals – particularly itraconazole – after seven weeks of exposure (Zhang J et al. 2017).

Resistance could arise in any environment where triazole fungicides are used and decaying plant matter provides habitat for *A. fumigatus.* Several studies have assessed stockpiles of plant waste for *A. fumigatus* populations and for presence of agricultural triazoles and their breakdown products. Schoustra et al. (2019) examined stockpiles of dead flower bulbs, green materials, and wood chips, finding substantial populations of *A. fumigatus* in each, ranging from roughly 10^3 to 10^5 colony-forming units (CFUs)/gram. Triazoles and their degradation products were found in most (78%) of 41 samples, at concentrations ranging from 0.001 to 6.4 ppm. Another study by the same team similarly found on average 10^5 CFUs/gram plant waste in 114 samples, and estimated a plant waste stockpile just 50 x 50 x 10 meters would contain 2.5 quadrillion (10^{15}) spores. Roughly half of the isolates were triazole-resistant, with 90% resistant to both itraconazole (medical) and tebuconazole (agricultural). They also found a variety of resistance mechanisms (Zhang J et al. 2021).

A. fumigatus is a common component of bioaerosols, and it is estimated that an average person inhales 200 spores (conidia) each day (Dagenais and Keller 2009). Inhalation of *A. fumigatus* spores in the air is thought to be the major route of infection. Aerial dispersal of *A. fumigatus* from compost piles has been demonstrated, with a surge in release when the piles are turned, and substantial quantities then found in the downwind air (Millner et al. 1977, 1980).

A recent literature review found that 1,292 azole-resistant isolates of *A. fumigatus* had been identified worldwide, over one-third of which were from agricultural environments (Burks et al. 2021). Of the total, 57% were detected in soil, 17% in air, 11% in plant debris and 9% in compost (Ibid.). The intensity of agricultural triazole use is highest in European countries, particularly The Netherlands; it is no coincidence that this is where the majority of resistant *A. fumigatus* strains, and especially those from agricultural environments, have been found (Ibid.).

Resistance is also beginning to emerge in the United States, where *A. fumigatus* strains with environmental-origin resistance mutations have been isolated from clinics since 2015 (Hurst et al. 2017). Resistance is detected in agricultural environments as well. Hurst et al. (2017) found triazole-resistant, TR34/L98H strains of *A. fumigatus* in the crop debris, soil and compost of Georgia peanut fields with a history of triazole exposure. Kang et al. (2020) isolated resistant strains with the other major environmental-origin mutation, TR46/Y121F/T289A, from samples taken from a strawberry field, pecan debris and a compost pile (source plants not identified) in 56 sites in Georgia and Florida.

Importantly, Kang et al. (2020) confirmed the agricultural origin of clinically relevant, azole-resistant *A. fumigatus* strains. They did this by establishing that some strains collected from both clinical and agricultural settings had *additional* resistance to one or both of two classes of fungicide – quinone outside inhibitors (QoI's) and benzimidazoles – that are only used in agriculture.

The sites of agriculture-origin, azole-resistant *A. fumigatus* strains discovered in the U.S. thus far include two crops – pecans and strawberries – for which propiconazole is registered.

EPA must assess the public health threats posed by continued and expanding use of propiconazole and other agricultural triazoles in terms of increasing resistance of human fungal pathogens

Environmental Fate of Propiconazole

Propiconazole is stable to abiotic hydrolysis and to photolysis in the soil and water. It is persistent in soil and stable in aqueous environments, with aerobic and anaerobic aquatic metabolism half-lives of 427 and 363 days, respectively (EPA 3/7/22, Table 5-2, pdf p. 79). Soil metabolism half-lives range from 43 to 70 days, but since the three tests were all conducted in silty loam soil, degradation in other soil types remains uncertain. Field dissipation half-lives were of similar length, but here too data are limited to sandy loam and silt loam soils (Ibid.). EPA identifies 5 major breakdown products, one of which is 1,2,4-triazole (CGA-71019), a degradate common to many triazole fungicides (Ibid., pdf pp. 78, 169). It is not clear that EPA has any empirical toxicity data for 4 of the 5 degradates, and as discussed above, there are critical data gaps for 1,2,4-triazole and its conjugates.

Environmental Impacts and Assessment Deficiencies

Aquatic Vertebrates

Fish:

Propiconazole is highly toxic to fish. EPA's assessment finds chronic risks for freshwater fish, with risk quotients (RQ's) ranging up to 2.5 for agricultural and 8.27 for non-agricultural uses (Ibid., Table 4-6, pdf p. 27). However, these estimates are uncertain because of a key data gap. EPA failed to collect a chronic (fish early life stage) study on the most sensitive freshwater species (as gauged by LD_{50} value), the rainbow trout, and instead guesstimated a no observed adverse effect concentration (NOAEC) for this species by applying an acute-to-chronic (ACR) ratio derived from fathead minnow data to the rainbow trout LD_{50}. This guesstimate was then used to calculate risk quotients (Ibid., pdf pp. 26, 80-82).

A second data gap relates to estuarine/marine fish, for which EPA lacks ***any*** valid data. The only such study is an acute toxicity test on the spot (*Leiostomus xanthurus*), which as EPA notes is not a "preferred test species" because not listed in the relevant test guideline (EPA 2016), and which was conducted with low dissolved oxygen levels that may have skewed the results (EPA 3/7/22, Table 6-1, pdf p. 82). EPA did not insist on a chronic study for an estuarine/marine fish,[21] even though required by its regulations. Instead, EPA played the same guesstimating game to fabricate an NOAEC for the spot (*Leisostomus xanthurus*), a fish that never should have been used for testing at all, based on the flawed acute spot study and the acute-to-chronic (ACR) data from the less sensitive freshwater fish, the fathead minnow (Ibid., pdf pp. 80-82).[22] Therefore, EPA's resulting chronic risk quotients for saltwater fish of up to 3.1 (for ornamental uses) are worth little.

Fortunately, higher quality data are available. In a study 10 of whose 11 authors are EPA scientists, Skolness et al. (2013) exposed fathead minnows to propiconazole at nominal concentrations of 5, 50, 500 and 1,000 ug/liter for 21 days. Among other findings, the fecundity of females as measured by cumulative egg production was reduced at all doses, significantly for the 5, 500 and 1,000 ug/liter groups. The authors also found disruption of steroidogenesis – for instance, reduced plasma estradiol and vitellogenin concentrations, and compensatory upregulation of genes encoding key steroidogenic CYP enzymes as well as STAR protein. Teng et al. (2020) exposed zebrafish to propiconazole for 120 days at doses of 0.1, 5 and 250 ug/liter: from embryonal stage 2 hours after fertilization until sexual maturity. In this study, too, fecundity of females decreased sharply at all doses, caused by disruption of steroidogenesis and alteration of DNA methylation patterns.

In these two studies, the lowest dose was also the lowest observed adverse effect concentration (LOAEC): 5 ug/l for Skolness et al. (2013) and 0.1 ug/l for Teng et al. (2020), both

[21] Registrants apparently simply decided not to do the required study. "No chronic endpoint was available for estuarine/marine fish as no data were submitted. An acute toxicity study using the freshwater fish, fathead minnow (MRID 50552203) was submitted in lieu of an early life-stage study with an estuarine/marine fish" (Ibid., pdf p. 80.). However, an ***acute*** study on a ***freshwater*** fish is no substitute for a ***chronic*** study on a ***saltwater*** fish.

[22] These computational gymnastics that EPA undertakes to paper over data gaps rather than demand the required studies are all too familiar. The more EPA gives registrants a pass on conducting needed studies, the more often they will take advantage and not submit them, and the more "uncertainties" creep into the Agency's risk assessments.

far below EPA's ACR-fabricated "LOAEC" and "NOAEC" for freshwater fish of 29 and 15 ug/l, respectively. We urge EPA to instead utilize the empirical data from these studies to establish a truly protective propiconazole safety threshold for fish.

A sufficiently protective threshold is particularly important in light three facts.

First, reduced egg production is perhaps the most frequently identified reproductive impact of azole fungicides. For instance, Chu et al. (2016) found that egg production resulting from the mating of male and female medaka fish both exposed early in life to triadimenol (a fungicide in its own right, and a breakdown product of another fungicide, triadimefon) was dramatically reduced (from 38 to 17 eggs/day) at concentrations as low as 3 ug/liter. Li et al. (2019) likewise found significant reductions in egg production, among other effects, in zebrafish exposed to tebuconazole from 60 to 120 days post-fertilization. Skolness et al. (2013) noted that conazoles as a class are known to be steroid synthesis inhibitors, and found "the overall pattern of responses" in their study to be "remarkably consistent" with the effects seen in other studies of fish exposed to conazoles – including reduced fecundity.

Second, as noted above the use of azole fungicides is increasing dramatically, meaning ever more situations in which fish will be exposed to higher concentrations of multiple azoles, with additive effects likely. With safety thresholds for the 15 or more azole fungicides applied in the U.S. established separately, without regard to simultaneous exposure to others, cumulative exposure to the class will easily exceed any individual threshold, without necessarily there being any exceedance of an individual threshold. This once again points to the need for a cumulative toxicity assessment of triazole fungicides, as argued above, and as completed by the European Food Safety authority over a decade ago (EFSA 2009).

Finally, reductions in cumulative egg production is an impact with direct relevance to the continued existence of the impacted species, making it an extremely important parameter in both general ecological and in particular endangered species assessments.

Aquatic-phase amphibians

When EPA lacks toxicity data for aquatic-phase amphibians, it typically uses freshwater fish as a surrogate species (EPA 3/7/22, pdf p. 102). But several studies of propiconazole's effects on amphibians are available. Hayes et al. (2006) exposed larval leopard frogs to propiconazole at a concentration of 0.23 ug/l from 2 days post-hatching until complete tail resorption (Gosner stage 46). They found a significant delay in time to initiate metamorphosis (foreleg emergence) and time to complete metamorphosis, each approximately 6 days. Timely metamorphosis is often critical since frogs often breed in ephemeral water sources, especially in agricultural areas, and tardy development will reduce survivorship. Propiconazole-exposed larvae also exhibited a negative (though not significant) relationship between time to complete metamorphosis and size at metamorphosis. This is significant because both slower development and smaller size are disadvantageous; as noted above, ephemeral water bodies dry up, stranding tardy developers, while smaller amphibians are less effective predators.

It should be noted that this study examined the effects of eight other pesticides individually, as well as the nine-pesticide combination (each at a nominal concentration of 0.1 ppb). While propiconazole was the only individual pesticide to delay metamorphosis, the nine-pesticide combination also had this effect, although considerably more pronounced. Thus, propiconazole may be the chief effector of this effect, which is enhanced by one or more other

pesticides in the combination. Similarly, only two or three pesticides other than propiconazole had a slight effect on the relationship between time to and size at metamorphosis, as discussed above. The authors suggest these three or four may additively account for all of the greater effect observed in the nine-pesticide mixture, or that the other pesticides in the mixture may act as enhancers.

In any case, EPA itself discusses this study. It is identified as ECOTOX study E085815 in Table 6-1: Aquatic Toxicity Endpoints Selected for Risk Estimation for Propiconazole (EPA 3/7/22, pdf p. 82); and EPA calculates pseudo LOAEC-based risk quotients of 41 to 600 based on this study – that is, modeled surface water concentrations ranging from 9.5 to 138 ug/l in different scenarios exceed the 0.23 ug/l LOAEC by 41 to 600 times (Ibid., pdf p. 24), where EPA clearly notes that these concentrations are sufficient to "elicit a toxic effect." Yet despite categorizing this study as one used for "risk estimation," EPA ignores it when setting the threshold for aquatic vertebrates, which as noted above is based on the derivative, ACR-fabricated, chronic "NOAEC" of 15 ug/l.

An amphibian metamorphosis study on propiconazole commissioned by Syngenta was submitted to EPA for the Endocrine Disruptor Screening Program, Tier 1 screening (EPA 6/29/15, pdf p. 48). In this assay utilizing the African clawed frog (*Xenopus laevis*), exposed to propiconazole for 21 days at three doses – 0.0056, 0.056 and 0.57 mg/l – 25% mortality was recorded for each dosage group, versus just 5% for the control group. Thus, the LOAEC for this study is 5.6 ug/l, well below EPA's chosen endpoint for aquatic vertebrates, discussed above: LOAEC of 29 and NOAEC of 15 ug/liter.

However, there are a number of anomalies that make this study less reliable than Hayes et al. (2006). The authors do not give detailed mortality data, and the limit of quantitation (LOQ) is extremely high. Nor do they offer any explanation for the 71% to 80% of tadpoles that exhibited spinal deformities in the control and treatment groups, casting serious doubt on the validity of the assay.

Terrestrial Invertebrates

In EPA's original risk assessment of propiconazole's effects on honeybees, the agency found chronic risk quotients for adult, nectar-foraging bees that ranged from >5 to >73, based on an NOAEC of < 0.78 ug/bee (EPA 3/7/22, pdf p. 134). They remain quite high in EPA's revised assessment, using mortality as an endpoint, with chronic RQ's ranging up to 14 and 9 for adult and larval bees, respectively (Ibid., p. 43).

EPA should also the impact of propiconazole in combination with insecticides, given that triazole fungicides are known to suppress the P450 detoxification enzymes that honeybees and other terrestrial invertebrates rely upon to detoxify insecticides. One of many examples in the literature is Wade et al. (2019), which assessed the toxicity of three insecticides and three fungicides commonly used on almond orchards in California. Chlorantraniliprole was found to increase mortality to larval bees when combined with propiconazole, but not alone. Similarly, the combination of chlorantraniliprole and propiconazole applied topically was highly toxic to worker bees.

Pilling and Jepson (1993) showed that the acute contact toxicity of lambda-cyhalothrin was synergized to varying degrees by propiconazole and eight other ergosterol biosynthesis

inhibiting (EIB) fungicides in tests involving binary mixtures of the pyrethroid and each fungicide, with topical application of the respective mixture at typical application rates.

Azole fungicides have been shown to synergize non-pyrethroid insecticides as well. When sprayed on honey bees, a binary mixture of tetraconazole and imidacloprid synergistically increased the lethality of imidacloprid by 20% (Zhu et al. 2017). Raimets et al. (2018) found that the EIB fungicide imazalil increased the lethality to bumblebees of fipronil and thiamethoxam as well as the pyrethroid cypermethrin. The mechanism with respect to pyrethroids and perhaps the other insecticides is EIB fungicides' well-known inhibition of detoxifying cytochrome P450 enzymes in bees and other organisms (Cedergreen 2014).

In a study conducted in the United Kingdom, both neonicotinoids and fungicides were detected frequently in the pollen of oilseed rape and nearby wildflowers (David et al. 2016). They were also detected in pollen collected by honey bees and bumblebees and stored in colonies and nests, respectively, placed in the vicinity of the oilseed rape fields. Fungicides, including EIB fungicides like tebuconazole, comprised the majority of pesticide residue in pollen of both honey bees and bumble bees. However, bumblebee pollen had higher levels of pesticide residues, perhaps reflecting greater exposure to fungicides due to their ground-nesting habit, and bumblebees are thus likely even more threatened by EIB fungicides than honey bees.

Fungicides in honey bee pollen end up in bee bread, and have been shown to reduce the levels of beneficial fungi that ferment bee bread, with potentially adverse effects on larval and colony health, including reduced protection from microbial pathogens (Yoder et al. 2013).

While we support EPA's plans to issue a data call-in for Tier II/III (semi-field and field) studies of propiconazole's toxicity to honeybees, we urge the Agency to go further and begin the task of assessing how propiconazole and other azole fungicides potentiate the toxicity of insecticides they are frequently applied with, either together or in close succession. EPA's long-time refrain is that it does assess pesticide mixtures in large part because there are too many possible combinations to assess. However, EPA could canvas the literature for toxic combinations such as Wade and colleagues demonstrate, and limit its assessment of mixture toxicity to those pesticides that are likely to be used together, and which demonstrate clear additive or synergistic toxicity.

In addition, it is a decade since a Scientific Advisory Panel told EPA it needed to begin collecting pesticide toxicity data on one or more additional bee species "to address the stated goal of protecting diversity," with suggestions that included the alfalfa leafcutting bee, a mason and orchard bee, or a representative bumblebee, in light of the fact that most bee species are ground-dwelling, with a very different exposure profile than the honey bee (SAP 2012).

EPA must go beyond collecting new studies on propiconazole's toxicity to bees, and assess the impact on bees and other terrestrial invertebrates of aggregate exposure to azole fungicides, and these fungicides in combination with insecticides whose toxicity they synergize.

Costs and Benefits

Putative benefits

At least 80% of propiconazole use in the U.S. is on soybean, corn and wheat (see graph above). The following discussion will focus on these field crops.

While agronomists are disturbed by the dramatically increasing use of fungicides of all sorts, the concern is especially acute for use on field crops like corn and soybeans, which began

around 2007 (see Hershman et al. 2011 and Wise and Mueller 2011 for the following discussion). These agronomists note that foliar fungicide applications were extremely rare on corn and soybeans until this time; to the small extent fungicides were used, it was for seed production or specialty corn varieties, where higher prices justified the expenditures.

Agronomists attribute the rise in fungicide use on corn and soybeans largely to marketing drives by fungicide manufacturers, who have had success selling farmers on fungicides for dubious "plant health" reasons rather than disease; to higher corn prices beginning in 2007; and to growers' prioritization of yield potential over disease-resistance in selection of corn hybrids. Another reason is bad agronomic practice – increased planting of corn-on-corn, which increases disease risk (Robertson and Mueller 2007). There is also a troubling "insurance treatment" approach to fungicide spraying that goes fundamentally against IPM principles to use a pesticide only when needed, and only when the expenditure delivers more benefit in yield than the cost of the pesticide and its application (Robertson and Mueller 2007).

EPA also needs to factor in alternatives to tetraconazole for disease control. In fact, an array of cultural practices like crop rotations and intercropping can greatly reduce fungal disease pressure and thus reduce or eliminate the "need" for fungicide treatments (Liebman and Wallace 2019). For instance, rotating strawberries with broccoli has proven to be an effective strategy to mitigate harm from the fungal disease Verticillium wilt (Shetty et al 1999).

Costs

Resistance to triazole/DMI fungicides has been building steadily over years, and together with widespread resistance to strobilurin and other classes of fungicide is a serious problem.

> "For decades, scientists have watched as fungi all over the world have become incrementally more and more resistant to DMI fungicides. The use of any fungicide for 'plant health' reasons increases the risk of developing resistance" (Hershman et al. 2011).

Clearly, superfluous use of fungicides like propiconazole – as for "plant health" reasons – must be avoided at all costs to stem or at least slow resistance development. The costs of resistance in agricultural practice are dwarfed by the human costs (i.e. deaths) resulting from the growing resistance to antifungal drugs in fungal pathogens that is attributable in part to intensive use of propiconazole and other triazoles (discussed above).

Propiconazole's use on corn and soybeans has risen substantially over the past decade (see graph above). Coupled with the rise in use of other triazoles, the area sprayed with or a triazole fungicide every year in the common corn-soybean rotation is rising sharply (Toda et al. 2021, Toda et al. 2021 Supplemental). This will intensify selection pressure for resistant plant and human fungal pathogens across the Corn Belt, where just 15-20 years ago hardly anyone saw any need to spray fungicides on these crops at all. Cross-resistance among triazole herbicides is common. For instance, even the fungicide manufacturers' group Fungicide Resistance Action Committee has stated: "Generally wise to accept that cross resistance is present between DMI fungicides active against the same fungus." (FRAC 2021, p. 11).

Mitigations

EPA's major mitigation for aquatic organisms is to put runoff control statements on propiconazole labels. Do not spray into bodies of water or when rain is expected within 24 hours; and do not apply or irrigate to the point of runoff (EPA PID 2022, pp. 33-38). EPA supplies no evidence these mitigations will be effective, and if so what degree of efficacy they may have. For instance, with LOAEC-based pseudo risk quotients for aquatic vertebrates of up to 600 (based on Hayes et al. 2006), these simple label messages would have to be extraordinarily effective to mitigate harm to sensitive amphibian and fish species. It is virtually certain that they would not be nearly effective enough to achieve anywhere near acceptable outcomes to amphibians and fish. Nor does EPA present any empirical assessment of whether the runoff statements would even be followed.

Threatened and Endangered Species

EPA has not completed an assessment of propiconazole for its impact on threatened and endangered species. EPA must comply with its duties under Section 7 of the Endangered Species Act (ESA) prior to finalizing its interim registration decision, as it is a separate, discretionary action that may affect species listed as threatened or endangered under the ESA. *See Nat. Res. Def. Council v. EPA*, 2022 WL 2184936, at *18 (9th Cir. June 17, 2022) (establishing that EPA must complete consultation for interim registration review decisions). Because there are many acknowledged risks of concern of propiconazole to a range of taxa, and imperiled species listed under the ESA are highly susceptive to additional threats, it is clear that listed species will continue to be put at risk with a registration review decision as EPA has proposed, and at still greater risk from registration of foliar use on corn.

Propiconazole may affect numerous threatened and endangered species across the country including, but not limited to, the species listed below.

Fish	
Neosho madtom	*Noturus placidus*
Pallid sturgeon	*Scaphirhynchus albus*
Topeka shiner	*Notropis topeka*
Terrestial Invertebrates	
Rusty patched bumblebee	*Bombus affinis*
Mitchell's Satyr Butterfly	*Neonympha mitchellii mitchellii*
Poweshiek skipperling	*Oarisma poweshiek*
Monarch butterfly (candidate)	*Danaus plexippus plexippus*

EPA must complete endangered species consultation to ensure the registration does not jeopardize the existence of species protected as threatened or endangered under the ESA prior to finalizing its registration decision. Without having fulfilled this duty under the ESA, in consultation with the expert wildlife agencies, EPA cannot determine the full impacts of difenoconazole on ESA-listed species and their critical habitats and ensure that it will not

jeopardize any of those species. What EPA is doing here is clearly not sufficient to comply with the ESA.

Bill Freese, Science Director
Center for Food Safety

References

Al-Eryani L. et al. (2015). Identification of environmental chemicals associated with the development of toxicant-associated fatty liver disease in rodents. Toxicologic Pathology 43: 482-497.

Altekruse SF et al. (2009). Hepatocellular carcinoma incidence, mortality, and survival trends in the United States From 1975 to 2005. Journal of Clinical Oncology 27(9): 1485-91.

Amrhein V et al. (2019). Retire statistical significance. Nature 567: 305-307 (March 21, 2019).

Angrish MM et al. (2016). Tipping the balance: Hepatotoxicity and the four apical key events of hepatic steatosis. Toxicol. Sci. 150(2): 261-268.

Barraclough D et al. (2005). Bound residues: environmental solution or future problem? Environmental Pollution 133: 85-90.

Bowyer P and Denning DW (2014). Environmental fungicides and triazole resistance in *Aspergillus*. Pest Management Science 70(2): 173-178.

Burks C et al. (2021). Azole-resistant *Aspergillus fumigatus* in the environment: identifying key reservoirs and hotspots of antifungal resistance. PLoS Pathogens 17(7): e1009711.

Cedergreen N (2014). Quantifying Synergy: A Systematic Review of Mixture Toxicity Studies within Environmental Toxicology. PLoS ONE 9(5): e96580.

Chauzat M-P et al. (2009). Influence of Pesticide Residues on Honey Bee (Hymenoptera: Apidae) Colony Health in France. Environmental Entomology 38(3): 514-523.

Chu A-H et al. (2016). Developmental exposures to an azole fungicide triadimenol at environmentally relevant concentrations cause reproductive dysfunction in females of medaka fish. Chemosphere 152: 181-189.

Dagenais TRT and Keller NP (2009). Pathogenesis of *Aspergillus fumigatus* in Invasive Aspergillosis. Clinical Microbiology Reviews 22(3): 447-64.

David A et al. (2016). Widespread contamination of wildflower and bee-collected pollen with complex mixtures of neonicotinoids and fungicides commonly applied to crops. Environment International 88: 169-178.

EFSA (2019). Establishment of cumulative assessment groups of pesticides for their effets on the thyroid. European Food Safety Authority, EFSA Journal 2019; 17(9): 5801.

EFSA (2011). Conclusion on the peer review of the pesticide risk assessment of the active substance tetraconazole. European Food Safety Authority, EFSA Journal 9(1): 1967.

EFSA (2009). Scientific Opinion on Risk Assessment for a Selected Group of Pesticides from the Triazole Group to Test Possible Methodologies to Assess Cumulative Effects from Exposure

through Food from these Pesticides on Human Health. European Food Safety Authority, EFSA Journal 7 (9); 1167.

Elcombe CR et al. (2014). Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator. Crit. Rev. Toxicol. 44(1): 64-82.

EPA (3/21/22). Propiconazole: Revised human health draft risk assessment of conventional uses to support registration review. EPA-HQ-OPP-2015-0459-0074, March 21, 2022.

EPA (3/10/22). Difenoconazole: Response to comments on the proposed interim decision. EPA-HQ-OPP-2015-0401-0063, March 10, 2022.

EPA (3/7/22). Propiconazole: Amendment to the Draft Ecological Risk Assessment for Registration Review. EPA-HQ-OPP-2015-0459-0071, March 7, 2022.

EPA (2021). Tetraconazole: Proposed Interim Registration Review Decision, Case No. 7043. EPA, September 2021.

EPA (6/28/21). Oxyfluorfen: Proposed Interim Registration Review Decision, Case Number 2490. EPA, June 28, 2021.

EPA (12/11/20). Tetraconazole. Draft Human Health Risk Assessment for Registration Review. EPA, December 11, 2020.

EPA (12/2/20). Tetraconazole: Draft Ecological Risk Assessment for Registration Review. EPA, December 2, 2020.

EPA (2018). Implementing the Pesticide Registration Improvement Act – Fiscal Year 2018. 15th Annual Report, EPA, 2018.

EPA (5/16/18). Tebuconazole: Pesticide Tolerances. 83 Fed. Reg. 22595-601 at 22600 (May 16, 2018).

EPA (2016). Ecological Effects Test Guidelines OCSPP 850.1400: Fish Early Life Stage Toxicity Test, EPA 712-C-16-008, EPA-HQ-OPP-2009-0154-0033, October 2016.

EPA (4/12/16). Pesticide Cumulative Risk Assessment: Framework for Screening Analysis Purpose, EPA, April 12, 2016. EPA-HQ-OPP-2015-0422-0019.

EPA (6/29/15). EDSP Weight of Evidence Analysis of Potential Interaction with Estrogen, Androgen or Thyroid Pathways for Propiconazole. EPA-HQ-OPP-2009-0634-0248, June 29, 2015.

EPA (2011). Integrated approaches to testing and assessment strategy: use of new computational and molecular tools. Environmental Protection Agency, Office of Pesticide Programs, paper for FIFRA Scientific Advisory Panel Consultation, EPA-HQ-OPP-0284-0006, April 25, 2011.

EPA (2/7/06). 1,2,4-Triazole, Triazole Alanine, Triazole Acetic Acid: Human Health Aggregate Risk Assessment in Support of Reregistration and Registration Actions for Triazole-derivative Fungicide Compounds. EPA, February 7, 2006.

EPA (2005). Tetraconazole Fact Sheet. EPA, April 2005.

EPA (1/14/02). Guidance on Cumulative Risk Assessment of Pesticide Chemicals That Have a Common Mechanism of Toxicity, EPA, January 14, 2002.

EPA (5/18/00). Tetraconazole use on sugar beets. Evaluation of residue data and analytical methods. EPA, May 18, 2000. https://www3.epa.gov/pesticides/chem_search/cleared_reviews/csr_PC-120603_18-May-00_b.pdf.

EPA (1/11/00). Tetraconazole – Report of the Cancer Assessment Review Committee. EPA, January 11, 2000. https://archive.epa.gov/pesticides/chemicalsearch/chemical/foia/web/pdf/120603/120603-002.pdf.

EPA (1/29/99). Guidance for Identifying Pesticide Chemicals and Other Substances That Have a Common Mechanism of Toxicity, EPA, January 29, 1999.

EPA (1998). Health Effects Test Guidelines. OPPTS 870.7600: Dermal Penetration. EPA 712-C-98-350, August 1998.

EPA (7/27/94). Carcinogenicity Peer Review of Difenoconazole. EPA, July 27, 1994.

Fisher MC et al. (2018). Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science 360: 739-42 (May 18, 29018).

FRAC (2021). FRAC Code List 2021:Fungal control agents sorted by cross resistance pattern and mode of action (including coding for FRAC Groups on product labels). Fungicide Resistance Action Committee, 2021.

Hayes T et al. (2006). Pesticide Mixtures, Endocrine Disruption, and Amphibian Declines: Are We Underestimating the Impact? Environmental Health Perspectives 114(Suppl. 1): 40-50.

Heise T et al. (2017). Hepatotoxic combination effects of three azole fungicides in a broad dose range. Arch Toxicol 92(2): 859-872.

Heise T, Schmidt F, Knebel C et al (2015). Hepatotoxic effects of (tri)azole fungicides in a broad dose range. Arch Toxicol 89(11): 2105–2117. https://doi.org/10.1007/s00204-014-1336-1.

Hershman DE, Vincelli P and Kaiser CA (2011). Foliar Fungicide Use in Corn and Soybeans. University of Kentucky College of Agriculture, Plant Pathology Fact Sheet, PPFS-GEN-12, October 2011.

Hurst SF et al. (2017). Isolation of azole-resistant Aspergillus fumigatus from the environment in the south-eastern USA. Journal of Antimicrobial Chemotherapy 72(9): 2443-46.

Kang SE et al. (2020). Evidence for the agricultural origin of antimicrobial resistance in a fungal pathogen of humans. G3 Genes|Genomes|Genetics, jkab427, https://doi.org/10.1093/g3journal/jkab427

Kjoller R and Rosendahl S (2000). Effects of fungicides on arbuscular mycorrhizal fungi: differential responses in alkaline phosphatase activity of external and internal hyphae. Biol Fertil Soils 31: 361-365.

Knebel C et al (2019). Pregnane X receptor mediates steatotic effects of propiconazole and tebuconazole in human liver cell lines. Archives of Toxicology 93(5): 1311-22.

Kwon H-C et al (2021). Effects of Flutriafol Fungicide on the Lipid Accumulation in Human Liver Cells and Rat Liver. Foods 10: 1346.

Lasch A et al (2021). More than additive effects on liver triglyceride accumulation by combinations of steatotic and non-steatotic pesticides in HepaRG cells. Archives of Toxicology 95: 1397-1411.

Li S et al. (2019). Endocrine disrupting effects of tebuconazole on different life stages of zebrafish (*Danio rerio*). Environmental Pollution 249: 1049-59.

Liebman A and Wallace R (2019). A factory farm fungus among us. Agroecology and Rural Economics Research Corps, April 10, 2019. https://arerc.wordpress.com/2019/04/10/a-factory-farm-fungus-among-us/.

Marx-Stoelting P et al (2020). The Connection of Azole Fungicides with Xeno-Sensing Nuclear Receptors, Drug Metabolism and Hepatotoxicity. Cells 9: 1192; doi:10.3390/cells9051192.

Millner PD et al. (1980). Dispersal of *Aspergillus fumigatus* from sewage sludge compost piles subjected to mechanical agitation in open air. Applied and Environmental Microbiology 39(5): 1000-09.

Millner PD et al. (1977). Occurrence of *Aspergillus fumigatus* during composting of sewage sludge. Applied and Environmental Microbiology 34(6): 765-772.

Nesnow et al. (2009). Discrimination of Tumorigenic Triazole Conazoles from Phenobarbital by Transcriptional Analyses of Mouse Liver Gene Expression. Toxicological Sciences 110(1): 68-83.

Nielsen E. et al. (2012). Identification of Cumulative Assessment Groups of Pesticides, External Scientific Report Submitted to EFSA [European Food Safety Authority]. National Food Institute, Technical University of Denmark, 2012

Pilling ED and Jepson PC (1993). Synergism between EBI fungicides and a pyrethroid insecticide in the honeybee (*Apis mellifera*). Pesticide Science 39: 293-297.

Raimets R et al. (2018). Synergistic interactions between a variety of insecticides and an EBI fungicide in dietary exposures of bumble bees (*Bombus terrestris L.*). Pest Management Science 74(3): 541-546.

Richtel M ad Jacobs A (2019). A Mysterious Infection, Spanning the Globe in a Climate of Secrecy: The rise of Candida auris embodies a serious and growing public health threat: drug-resistant germs. The New York Times, April 6, 2019.

Robertson A and Mueller D (2007). Before applying fungicides to corn: Stop! Look! Consider! Iowa State University Extension and Outreach, July 2, 2007. https://crops.extension.iastate.edu/encyclopedia/applying-fungicides-corn-stop-look-consider.

Roman DL et al. (2021). Effects of Triazole Fungicides on Soil Microbiota and on the Activities of Enzymes Found in Soil: A Review. Agriculture 11: 893. https://doi.org/10.3390/ agriculture11090893.

Roszko ML et al. (2016). Levels of Selected Persistent Organic Pollutants (PCB, PBDE) and Pesticides in Honey Bee Pollen Sampled in Poland. PLoS ONE 11(12): e0167487.

SAP (2012). A Set of Scientific Issues Being Considered by the Environmental Protection Agency Regarding Pollinator Risk Assessment Framework. FIFRA Scientific Advisory Panel Report No. 2012-06. Meeting Sept. 11-14, 2012. EPA-HQ-OPP-2012-0543-0047, Dec. 10, 2012.

Schoustra SE et al. (2019). Environmental Hotspots for Azole Resistance Selection of *Aspergillus*
fumigatus, the Netherlands. Emerging Infectious Diseases 25(7): 1347-53.

Shetty KG et al. (1999). Management of Verticillium wilt in strawberry using vegetable crop rotation.
https://crec.ifas.ufl.edu/extension/soilipm/1999%20MBAO/Shetty,%20K.G/Shetty,%20K.G.%20(49)%201999%20Presentation.pdf.

Skolness SY et al. (2013). Propiconazole Inhibits Steroidogenesis and Reproduction in the Fathead Minnow (*Pimephales promelas*), Toxicological Sciences 132(2): 284-297.

Snelders E et al (2012). Triazole Fungicides Can Induce Cross-Resistance to Medical Triazoles in *Aspergillus fumigatus*. PLoS One 7(3): e31801.

Teng M et al. (2020). Life cycle exposure to propiconazole reduces fecundity by disrupting the T steroidogenic pathway and altering DNA methylation in zebrafish (*Danio rerio*). Environment International 135: 105384.

Toda M. et al. (2021). Trends in Agricultural Triazole Fungicide Use in the United States, 1992–2016 and Possible Implications for Antifungal-Resistant Fungi in Human Disease. Environmental Health Perspectives 129(5), May 2021. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098123/pdf/ehp7484.pdf.

Toda et al. (2021), Supplemental. Supplemental materials for paper cited above.

Wade A et al. (2019). Combined Toxicity of Insecticides and Fungicides Applied to California Almond Orchards to Honey Bee Larvae and Adults. Insects 10:20, doi:10.3390/insects10010020

Wahlang B et al. (2013). Toxicant-Associated Steatohepatitis. Toxicol. Pathol. 41(2): 343-360.

Wang Y, Zhu YC, Li W (2020). Comparative examination on synergistic toxicities of chlorpyrifos, acephate, or tetraconazole mixed with pyrethroid insecticides to honey bees (*Apis mellifera L.*). Environ Sci Pollut Res Int 2020 Mar;27(7):6971-6980.

Wise K and Mueller D (2011). Are Fungicides No Longer Just For Fungi? An Analysis of Foliar Fungicide Use in Corn. American Phytopathological Society, APSnet Features. doi:10.1094/APSnetFeature-2011-0531.

Yang G et al. (2021). Combined toxic impacts of thiamethoxam and four pesticides on the rare minnow (*Gobiocypris rarus*). Environmental Science and Pollution Research 28: 5407-16.

Yoder JA et al. (2013). Fungicide contamination reduces beneficial fungi in bee bread based on an area-wide field study in honey bee, *Apis mellifera*, colonies. Journal of Toxicology and Environmental Health, Part A 76: 587-600.

Zhang J et al. (2021). Dynamics of *Aspergillus fumigatus* in Azole Fungicide-Containing Plant Waste in the Netherlands (2016–2017). Applied and Environmental Microbiology 87(2): e02295-20.

Zhang J et al. (2017). Evolution of cross-resistance to medical triazoles in *Aspergillus fumigatus* through selection pressure of environmental fungicides. Proc Biol Sci. 284(1863): 20170635.

Zhu YC et al. (2017). Synergistic toxicity and physiological impact of imidacloprid alone and binary mixtures with seven representative pesticides on honey bee (*Apis mellifera*). PLoS ONE 12(5): e0176837.